Introduction
============

Lung cancer is a leading cause of cancer-related deaths worldwide, including in South Korea \[[@b1-crt-2018-704]\]. Although smoking is one of the most important risk factors for lung cancer, the proportion of never-smokers with lung cancer is generally higher in Asian than in Western populations \[[@b2-crt-2018-704],[@b3-crt-2018-704]\]. In addition, mutations in the epidermal growth factor receptor (*EGFR*) gene, which could be used as a therapeutic target, are more frequent in Asian than in Western lung cancer patients \[[@b4-crt-2018-704]\].

The first nationwide lung cancer survey in South Korea, conducted by the Korean Academy of Tuberculosis and Respiratory Diseases in 1997 \[[@b5-crt-2018-704]\], found that squamous cell carcinoma was the most common histologic type. In contrast, the second nationwide lung cancer survey, conducted by the Korean Association for Lung Cancer in 2005 \[[@b6-crt-2018-704]\], found that adenocarcinoma was the leading histologic type and that lack of symptoms was associated with favorable outcomes.

Generally, female sex is a favorable prognostic factor for lung cancer \[[@b7-crt-2018-704],[@b8-crt-2018-704]\]. However, many of these studies were performed in limited groups of patients with specific conditions, such as non-small cell lung cancer (NSCLC) alone \[[@b9-crt-2018-704]\], or in those treated with certain modalities \[[@b10-crt-2018-704]\].

To build an unbiased and informative lung cancer registry, the Korean Association for Lung Cancer (KALC) developed a registry (KALC-R) in cooperation with the Korean Central Cancer Registry (KCCR), and surveyed about 10% of lung cancer cases. This study investigated epidemiology, clinical characteristics and sex differences in Korean lung cancer patients using data from the KALC-R of the year 2014.

Materials and Methods
=====================

1. Study populations and methods
--------------------------------

In 2014, the KCCR registered 24,253 patients newly diagnosed with lung cancer. Among these patients, several patients were excluded with KCCR selection criteria (such as excluding patients who enrolled more than one institution), the total survey population was 21,960 patients. The final survey population comprised 13 regional cancer centers and 39 hospitals from which significant number of registrations were made. Sample size in each hospital (cluster) was determined by selection probability based on the number of registration in each hospital. And patients of each hospital were sorted by date of first diagnosis, sex, age, and Surveillance, Epidemiology, and End Results program (SEER) summary stage. Two thousand six hundred forty patients were selected from each of 52 hospitals using a systematic sampling method \[[@b11-crt-2018-704]\]. In a process of survey, 19 patients with multiple primary cancer were excluded. In conclusion, 2,621 patients were analyzed in this paper.

A standardized protocol was used to collect data regarding patient age, sex, body mass index (BMI), smoking history, histopathologic tumor type, symptoms, performance status (PS), Eastern Corporative Oncology Group (ECOG) score, clinical stage (according to the seventh edition of the TNM International Staging System), treatment modality, results of molecular tests including *EGFR* mutation and anaplastic lymphoma kinase (*ALK*) translocation, and survival status. We defined ever-smokers those with any history of smoking prior to index lung cancer and never-smokers as those with no smoking history. Information such as BMI and PS was obtained in the initial date of visit at the time of diagnosis. Patie-nts were followed up until December 2017.

2. Statistical analysis
-----------------------

Continuous variables are expressed as mean±standard deviation (SD) or median (interquartile range \[IQR\]), and categorical variables as percentages. Continuous variables were compared using a Mann-Whitney U test, and categorical variables using chi-square or Fisher exact test, as appropriate. Risk factors for mortality were analyzed using Cox proportional hazards models. Variables with a p-value of \< 0.20 on univariate analysis were used in the multivariate analysis. Survival was analyzed by the Kaplan-Meier method and compared by log-rank tests. All p-values were two-tailed, with statistical significance set at p \< 0.05. All statistical analyses were performed using SPSS ver. 20.0 (IBM Corp., Armonk, NY).

3. Ethical statement
--------------------

The study protocol was reviewed and approved by the Institutional Review Board at the National Cancer Center (NCC2018-0193), which waived the requirement for informed consent due to the retrospective nature of the study.

Results
=======

1. Patient characteristics
--------------------------

A total of 2,621 lung cancer patients were enrolled at 52 sites in South Korea; there were no differences in sex and age category between survey population and sample ([Table 1](#t1-crt-2018-704){ref-type="table"}). Baseline characteristics of enrolled patients are shown in [Table 2](#t2-crt-2018-704){ref-type="table"}. The median patient age was 70 years (IQR, 61 to 76 years), 71.6% were men (lower than that in previous studies (79.3% in 1997 and 75.8% in 2005) and men were older than women (median age, 70 years vs. 68 years; p=0.002). Smoking history was significantly more frequent (84.0% vs. 12.5%, p \< 0.001) and mean BMI was significantly lower (22.7 kg/m^2^ vs. 23.6 kg/m^2^, p \< 0.001) in men than in women. Of all patients, 13.7% were asymptomatic at the time of diagnosis, with men being more likely to have symptoms such as cough, sputum, hoarseness, hemoptysis, and weight loss, than women. In case of histopathology, adenocarcinoma (48.4%) was the leading subtype in total patients. While adenocarcinoma was more common in woman (74.8% vs. 38.0%, p \< 0.001) compared to male patients, squamous cell carcinoma and small cell carcinoma were more common in male patients.

Among patients with NSCLC, 28.4% had stage I, 8.5% had stage II, 18.1% had stage III, and 45.0% had stage IV disease. The proportion of patients with stage I NSCLC was higher in women (38.7%) than in men (23.8%), whereas the proportion of patients with stage IV tumors was similar (44.1% vs. 45.4%). Among patients with NSCLC, 37.6% of patients received surgery as the initial treatment, 29.0% were treated with chemotherapy, 8.3% received radiation therapy, and 12.8% received no specific anti-cancer treatment. Surgery was significantly more frequent in women than in men (45.5% vs. 34.1%, p \< 0.001), whereas radiation therapy (5.2% vs. 9.7%, p \< 0.001), concurrent chemoradiation therapy (2.6% vs. 5.0%, p=0.010), and best supportive care (9.7% vs. 14.1%, p=0.004) were significantly less frequent in women.

Among patients with small cell lung cancer (SCLC), 36.6% had limited-stage and 63.4% had extensive-stage disease. Almost 60% of SCLC patients were treated with chemotherapy as the initial treatment, 15.4% received concurrent chemoradiation therapy, and 12.9% received no specific anticancer treatment. There were no sex-associated differences in clinical staging and initial treatment modalities in patients with SCLC.

2. Patient characteristics by smoking history
---------------------------------------------

Among 2,580 patients with smoking history, 939 (36.4%) were never-smokers. The comparison of characteristics between ever-smokers and never-smokers is shown in [Table 3](#t3-crt-2018-704){ref-type="table"}. The never-smoker group had fewer men (31.5% vs. 94.4%, p \< 0.001), and showed higher BMI (23.4 kg/m^2^ vs. 22.6 kg/m^2^, p \< 0.001) compared with the ever-smoker group. In addition, the never-smoker group included more asymptomatic patients (16.7% vs. 12.2%, p=0.001), and had better PS than did the ever-smoker group (p=0.045). Among patients with NSCLC, the incidence of stage I disease was higher in never-smokers (36.8%) than in ever-smokers (23.3%), whereas that of stage IV disease was similar (45.5% vs. 44.2%). Among patients with SCLC, never-smokers had more extensive-stage disease than did ever-smokers (75.9% vs. 60.8%, p=0.030).

Clinicopathologic characteristics of patients classified by sex and smoking habits are shown in [Table 4](#t4-crt-2018-704){ref-type="table"}. Of the 2,580 patients with available smoking history, 43.3% smoked over 30 pack-years, 20.3% smoked less than 30 pack-years, and 36.4% were never-smokers. The proportions of women in these three groups were 2.8%, 11.6%, and 68.5%, respectively. There were no sex-associated differences in clinicopathologic characteristics of patients who ever-smoked. However, assessments of never-smokers showed that women were younger (median, 68 years vs. 71 years; p=0.003), were more likely to have adenocarcinoma histology (79.9% vs. 56.1%), and had an earlier NSCLC clinical stage than did men.

3. Prognostic factor and survival analysis
------------------------------------------

The 2,265 NSCLC patients were followed up for a median of 17 months (IQR, 5 to 32 months), during which 1,321 patients (58.3%) died. Univariate Cox analysis showed that old age, male sex, ever-smoker status, low BMI, poor PS, higher clinical stage, squamous cell carcinoma histology (compared with adenocarcinoma), and non-surgical therapy or best supportive care (compared with surgery) were significant predictors of mortality. On multivariate Cox analysis, these clinical variables, except for ever-smoker and squamous cell carcinoma histology, remained significant prognostic factors ([Table 5](#t5-crt-2018-704){ref-type="table"}). Among NSCLC patients, median survival was significantly longer for women than for men (not reached vs. 13 months, p \< 0.001) ([Fig. 1A](#f1-crt-2018-704){ref-type="fig"}) and survival significantly differed with clinical stage at diagnosis ([Fig. 1B](#f1-crt-2018-704){ref-type="fig"}).

The 356 SCLC patients were followed up for a median of 8 months (IQR, 2 to 16 months), during which 306 patients (86.0%) died. Univariate and multivariate Cox analyses showed that older age, lower BMI, poor PS, extensive stage, and best supportive care were significant predictors of mortality ([Table 6](#t6-crt-2018-704){ref-type="table"}). Although ever-smoker seemed to be a favorable prognostic factor on univariate analysis, ever-smokers were younger and tended to have a more limited stage than did never-smokers ([S1 Table](#SD1-crt-2018-704){ref-type="supplementary-material"}). Although median survival was similar in men and women with SCLC (8 months vs. 8 months, p=0.785) ([Fig. 1C](#f1-crt-2018-704){ref-type="fig"}), survival significantly differed with clinical stage at diagnosis ([Fig. 1D](#f1-crt-2018-704){ref-type="fig"}).

4. Molecular profile and survival analysis among patients with adenocarcinoma in the year 2014
----------------------------------------------------------------------------------------------

Of the 571 patients diagnosed with stage IV adenocarcinoma, 339 (59.4%) were men ([Table 7](#t7-crt-2018-704){ref-type="table"}). *EGFR* mutations were analyzed in 496 (86.9%) patients, and 182 patients (36.8%) had mutations. Although mutation frequency was significantly higher in women than in men (51.2% vs. 26.6%, p \< 0.001), the proportion of mutation-positive men and women treated with a targeted agent did not differ. *ALK* translocation was analyzed in 109 patients and 15 patients (13.8%) showed *ALK* translocation. Although translocation frequency was not different among women and men (15.7% vs. 12.1%, p=0.584), the proportion treated with a targeted agent was higher in women than in men (75.0% vs. 14.3%, p=0.041).

Patients with stage IV adenocarcinoma were followed up for a median of 10 months (IQR, 3 to 23 months), during which 437 patients (76.5%) died. On univariate Cox analysis, older age, male sex, ever-smoker status, lower BMI, and poor PS were associated with mortality, and target driver mutation (*EGFR* mutation and/or *ALK* translocation) was associated with a favorable outcome. On multivariate Cox analysis, old age, low BMI, poor PS, and target driver mutation remained significant independent predictors of mortality ([S2 Table](#SD2-crt-2018-704){ref-type="supplementary-material"}). Women had improved survival (median 15 vs. 8 months, p \< 0.001) ([Fig. 2A](#f2-crt-2018-704){ref-type="fig"}) compared to men in patients with stage IV adenocarcinoma. In addition, patients who harbored *EGFR* mutations showed better prognosis (18 months vs. 8 months, p \< 0.001) ([Fig. 2B](#f2-crt-2018-704){ref-type="fig"}) than did patients without *EGFR* mutations. Among patients with stage IV adenocarcinoma and *EGFR* mutations, patients treated with a target agent showed better prognosis (21 months vs. 13 months, p=0.027) than those who were not treated.

Discussion
==========

Relative to patients of other ethnicities, Asians with lung cancer have generally been reported to have a lower prevalence of smoking and a higher prevalence of tumor-associated *EGFR* mutations; these factors may be responsible for the more favorable prognosis in Asians \[[@b12-crt-2018-704]\]. Our nationwide survey, showing the clinical characteristics of lung cancer in South Korea, yielded results comparable to those in other studies of Asian patients. In contrast to prior nationwide surveys in Korea, which was conducted by academic societies, this is the first unbiased statistic data of Korean nationwide lung cancer survey.

Unbiased and reliable epidemiological data are important to identify time trends in diseases and to establish government policy. Although two previous nationwide surveys were performed in South Korea, potential selection bias could not be ruled out during registration of cases at the individual hospital level. Since all patients with confirmed disease codes of C34 are registered in the KCCR, KCCR data have the advantage of including nearly all lung cancer patients without selection bias. The KALC and KCCR have formulated a lung cancer-specific registration system (KALC-R), which has about 80 data fields for demographic data, symptoms, smoking history, histological findings, staging data, molecular study results, and initial treatment details \[[@b13-crt-2018-704]\]. Recently, our group reported on a pilot survey of 489 patients diagnosed with lung cancer in 2013 \[[@b14-crt-2018-704]\]; the demographic characteristics were comparable with those from other studies based on the nationwide registry \[[@b15-crt-2018-704],[@b16-crt-2018-704]\]. In the current study, among 24,253 newly diagnosed lung cancer patients, about 10% were surveyed from 52 hospitals by a systematic sampling method, which helped eliminate potential bias in sample selection.

The epidemiology of lung cancer in South Korea have changed over time, major recent changes in epidemiology are summarized in [S3 Fig](#SD3-crt-2018-704){ref-type="supplementary-material"}. Compared to previous registry-based studies, the incidence of adenocarcinoma increased over the study period in both men and women. In 1997, although the most frequent histological type was squamous cell carcinoma (44.7%), adenocarcinoma incidence has increased over time, and has been the most incident histologic type since 2005. This observation may be explained by changes in cigarette components as well as by risk factors not related to smoking such as occupational risk and air pollution \[[@b17-crt-2018-704]\]. In addition to changes in histologic type prevalence, the development of screening methods such as low-dose chest computed tomography have led to an increased incidence of asymptomatic, early, and peripherally located cancers \[[@b18-crt-2018-704]\]. Thus, percutaneous lung biopsy has been most commonly performed for tissue confirmation. Additionally, the frequent use of positron emission tomography with computed tomography (PET-CT) has resulted in increased proportions of patients with stage IV lung cancer. Moreover, the use of PET-CT has made evaluation and characterization of the mediastinal lymph node more feasible; the endobronchial ultrasound-guided transbronchial needle aspiration has gained popularity and is an important diagnostic tool, especially in clinically evident N2 NSCLC \[[@b19-crt-2018-704]\].

Although smoking is one of the most important causes of lung cancer, the prevalence of cigarette smoking is decreasing in Korea, according to the Korea National Health and Nutrition Examination Survey \[[@b20-crt-2018-704]\]. In addition, the magnitude of the effect of smoking on lung cancer is smaller in Asian than in Western populations, a phenomenon termed the smoking paradox \[[@b21-crt-2018-704]\]. Asians are generally older at smoking initiation than are Westerners, and prefer less toxic or filtered tobacco. In contrast, the incidence of lung cancer among never-smokers is higher in Asian populations \[[@b2-crt-2018-704]\]. Genetic differences such as higher EGFR gene mutation rates in Asian populations and poor ventilation combined with the use of coal may explain these findings \[[@b22-crt-2018-704]\]. Indeed, about 87.5% of women patients in this survey had no smoking history. Additional studies are required to determine the potential risk factors for lung cancer in never-smokers.

Compared with previous registry-based studies, the incidence of lung cancer in women was higher in this study. Among patients with NSCLC, women had more favorable outcomes than did men, in agreement with previous studies showing better survival outcomes in women than in men with lung cancer \[[@b9-crt-2018-704],[@b23-crt-2018-704]\]. Generally, women are diagnosed with lung cancer at a younger age and include a higher percentage of non-smokers, and both these factors are associated with more favorable outcomes. These differences may partly be due to differences in genetic background and hormonal status \[[@b24-crt-2018-704]\], which affect susceptibility to carcinogens. In addition, because women are more likely to have adenocarcinoma primarily located peripherally \[[@b25-crt-2018-704]\], the impact of early diagnosis on survival may be greater in women than in men. *EGFR* mutations are more frequent in women than in men \[[@b26-crt-2018-704]\], which may contribute to survival advantages. Treatment with targeted agents has been associated with favorable outcomes in patients positive for *EGFR* mutations and may contribute to the sex differences in survival \[[@b27-crt-2018-704]\]. However, sex was not associated with survival in patients with SCLC, in contrast to findings from studies in Western populations \[[@b28-crt-2018-704],[@b29-crt-2018-704]\]. Among the 356 SCLC patients, only 53 (14.9%) were women. Although sex was not a prognostic factor with statistical significance in this small group of SCLC patients, additional studies in larger populations are needed to confirm this finding.

Among patients with stage IV adenocarcinoma and tested for *EGFR* mutation, 36.8% were positive for *EGFR* mutations. *EGFR* mutations were more common in women than in men, similar to the findings of previous studies in Asian populations \[[@b4-crt-2018-704]\]. Generally, compared to Western populations, Asians show higher *EGFR* mutation rates; this may contribute to the more favorable clinical outcomes observed in Asians \[[@b30-crt-2018-704]\]. The present study found that target driver mutations including *EGFR* mutations were significant prognostic factors, even after adjusting for other clinical variables. Although EGFR tyrosine kinase inhibitors have shown efficacy \[[@b27-crt-2018-704]\], *EGFR* mutation tests were not performed in all of our patients, though it is possible that test data were not provided during this survey for some cases. However, physicians should be aware of the need to test for *EGFR* mutations in all patients with advanced adenocarcinoma.

This study had several limitations. First, the retrospective study design resulted in an unavoidable deficiency of information such as second-hand smoking status and risk factors other than smoking. However, the strength of the study lies in the unbiased sampling method used to sample a representative population of patients with lung cancer. Second, disease-free survival and progression-free survival rates, as well as complete treatment modalities, could not be analyzed. However, overall survival rate is an acceptable, clear-cut, and important primary outcome. Finally, although the number of patients in this study was relatively large, it was not adequate to perform meaningful comparisons within subgroups with specific conditions. However, we believe that the present study will help in understanding the current trends in the epidemiology of lung cancer and may serve as a reference for future studies.

In conclusion, the evaluation of this unbiased nationwide survey dataset revealed female had a high proportion of non-smoker, more adenocarcinoma with *EGFR* mutation and generally better prognosis than male. And more than one-third of lung cancer patients had no smoking history. The results of this study show that the development of more effective early lung cancer screening and health insurance programs for lung cancer are indicated.
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Baseline characteristics of small cell lung cancer (SCLC) patients according to smoking history
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Risk factors for mortality in patients with stage IV adenocarcinoma assessed using Cox proportional hazards models

###### 

Nationwide trends in the epidemiology of lung cancer in South Korea.
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###### 

Comparison of sex and age category between survey population and sample

                                           Survey population   Sample         p-value
  ---------------------------------------- ------------------- -------------- ---------
  **No. of patients**                      21,960              2,621          
  **Male sex**                             15,500 (70.6)       1,876 (71.6)   0.291
  **Age category (yr) (total patients)**                                      
   \< 40                                   245 (1.1)           29 (1.1)       0.524
   40-50                                   926 (4.2)           121 (4.6)      
   50-60                                   3,416 (15.6)        424 (16.2)     
   60-70                                   5,996 (27.3)        734 (28.0)     
   ≥ 70                                    11,377 (51.8)       1,313 (50.1)   
  **Age category (yr) (male patient)**                                        
   \< 40                                   119 (0.8)           15 (0.8)       0.563
   40-50                                   511 (3.3)           72 (3.8)       
   50-60                                   2,204 (14.2)        283 (15.1)     
   60-70                                   4,487 (29.0)        542 (28.9)     
   ≥ 70                                    8,179 (52.8)        964 (51.4)     
  **Age category (yr) (female patient)**                                      
   \< 40                                   126 (2.0)           14 (1.9)       0.617
   40-50                                   415 (6.4)           49 (6.6)       
   50-60                                   1,212 (18.8)        141 (18.9)     
   60-70                                   1,509 (23.4)        192 (25.8)     
   ≥ 70                                    3,198 (49.5)        349 (46.9)     

Values are presented as number (%).

###### 

Baseline characteristics of study patients in the year 2014

                                             Total          Men            Women        p-value
  ------------------------------------------ -------------- -------------- ------------ ----------
  **No. of patients**                        2,621          1,876 (71.6)   745 (28.4)   
  **Age (yr)**                               70 (61-76)     70 (62-76)     68 (58-75)   0.002
  **Ever-smoker (n=2,580)**                  1,641 (63.6)   1,549 (84.0)   92 (12.5)    \< 0.001
  **BMI (kg/m^2^)**                          22.9±3.6       22.7±3.5       23.6±3.7     \< 0.001
  **Symptoms**                                                                          
   Asymptomatic                              360 (13.7)     239 (12.7)     121 (16.2)   0.019
   Cough                                     922 (35.2)     689 (36.7)     233 (31.3)   0.008
   Sputum                                    564 (21.5)     446 (23.8)     118 (15.8)   \< 0.001
   Dyspnea                                   534 (20.4)     380 (20.3)     154 (20.7)   0.812
   Hoarseness                                46 (1.8)       40 (2.1)       6 (0.8)      0.020
   Hemoptysis                                157 (6.0)      139 (7.4)      18 (2.4)     \< 0.001
   Weight loss                               168 (6.4)      136 (7.2)      32 (4.3)     0.005
   Pain                                      512 (19.5)     369 (19.7)     143 (19.2)   0.782
  **Histopathology**                                                                    
   Adenocarcinoma                            1,269 (48.4)   712 (38.0)     557 (74.8)   \< 0.001
   Squamous cell carcinoma                   654 (25.0)     597 (31.8)     57 (7.7)     \< 0.001
   Small cell carcinoma                      356 (13.6)     303 (16.2)     53 (7.1)     \< 0.001
   Others                                    354 (13.5)     272 (14.5)     82 (11.0)    0.019
  **Performance status (n=1,873)**                                                      
   0-1                                       1,756 (93.8)   1,235 (93.2)   521 (95.1)   0.129
   2-4                                       117 (6.2)      90 (6.8)       27 (4.9)     
  **Clinical stage of NSCLC (n=2,234)**                                                 
   I                                         634 (28.4)     369 (23.8)     265 (38.7)   \< 0.001
   II                                        190 (8.5)      146 (9.4)      44 (6.4)     
   III                                       405 (18.1)     331 (21.4)     74 (10.8)    
   IV                                        1,005 (45.0)   703 (45.4)     302 (44.1)   
  **Initial treatment of NSCLC (n=2,265)**                                              
   Surgery                                   851 (37.6)     536 (34.1)     315 (45.5)   \< 0.001
    Surgery only                             563 (66.2)     343 (64.0)     220 (69.8)   
    Surgery and adjuvant therapy             288 (33.8)     193 (36.0)     95 (30.2)    
   RT only                                   188 (8.3)      152 (9.7)      36 (5.2)     \< 0.001
   CCRT                                      96 (4.2)       78 (5.0)       18 (2.6)     0.010
   Chemotherapy                              657 (29.0)     456 (29.0)     201 (29.0)   0.978
   Best supportive care                      289 (12.8)     222 (14.1)     67 (9.7)     0.004
   Unknown                                   184 (8.1)      129 (8.2)      55 (7.9)     0.839
  **Clinical stage of SCLC (n=350)**                                                    
   Limited stage                             128 (36.6)     109 (36.7)     19 (35.8)    0.906
   Extensive stage                           222 (63.4)     188 (63.3)     34 (64.2)    
  **Initial treatment of SCLC (n=356)**                                                 
   Surgery                                   10 (2.8)       9 (3.0)        1 (1.9)      1.000
   RT only                                   17 (4.8)       14 (4.6)       3 (5.7)      0.727
   CCRT                                      55 (15.4)      46 (15.2)      9 (17.0)     0.738
   Chemotherapy                              213 (59.8)     186 (61.4)     27 (50.9)    0.153
   Best supportive care                      46 (12.9)      36 (11.9)      10 (18.9)    0.162
   Unknown                                   15 (4.2)       12 (4.0)       3 (5.7)      0.570

Values are presented as median (interquartile range), number (%), or mean±standard deviation. BMI, body mass index; NSCLC, non-small cell lung cancer; RT, radiation therapy; CCRT, concurrent chemoradiation therapy; SCLC, small cell lung cancer.

###### 

Comparison of characteristics between ever-smoker and never-smoker participants

                                          Total          Ever-smoker    Never-smoker   p-value
  --------------------------------------- -------------- -------------- -------------- ----------
  **No. of patients**                     2,580          1,641 (63.6)   939 (36.4)     
  **Male sex**                            1,845 (71.5)   1,549 (94.4)   296 (31.5)     \< 0.001
  **Age (yr)**                            69 (61-76)     70 (62-76)     69 (59-76)     0.055
  **BMI (kg/m^2^)**                       22.9±3.5       22.6±3.5       23.4±3.6       \< 0.001
  **Symptoms**                                                                         
   Asymptomatic                           357 (13.8)     200 (12.2)     157 (16.7)     0.001
   Cough                                  913 (35.4)     630 (38.4)     283 (30.1)     \< 0.001
   Sputum                                 557 (21.6)     407 (24.8)     150 (16.0)     \< 0.001
   Dyspnea                                527 (20.4)     358 (21.8)     169 (18.0)     0.021
   Hoarseness                             46 (1.8)       37 (2.3)       9 (1.0)        0.017
   Hemoptysis                             156 (6.0)      129 (7.9)      27 (2.9)       \< 0.001
   Weight loss                            167 (6.5)      128 (7.8)      39 (4.2)       \< 0.001
   Pain                                   508 (19.7)     326 (19.9)     182 (19.4)     0.766
  **Performance status (n=1,857)**                                                     
   0-1                                    1,743 (93.9)   1,091 (93.0)   652 (95.3)     0.045
   2-4                                    114 (6.1)      82 (7.0)       32 (4.7)       
  **Clinical stage of NSCLC (n=2,201)**                                                
   I                                      631 (28.7)     311 (23.3)     320 (36.8)     \< 0.001
   II                                     187 (8.5)      127 (9.5)      60 (6.9)       
   III                                    399 (18.1)     305 (22.9)     94 (10.8)      
   IV                                     984 (44.7)     589 (44.2)     395 (45.5)     
  **Clinical stage of SCLC (n=344)**                                                   
   Limited stage                          126 (36.6)     112 (39.2)     14 (24.1)      0.030
   Extensive stage                        218 (63.4)     174 (60.8)     44 (75.9)      

Values are presented as number (%), median (interquartile range), or mean±standard deviation. BMI, body mass index; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

###### 

Clinicopathologic characteristics of patients according to smoking frequency, stratified by sex (total=2,580)

                             Ever-smoker (≥ 30 pack years, n=1,116, 43.3%)   Ever-smoker (\< 30 pack years, n=525, 20.3%)   Never-smoker (n=939, 36.4%)                                                               
  -------------------------- ----------------------------------------------- ---------------------------------------------- ----------------------------- ------------ ------------ ------- ------------ ------------ ----------
  **No. of patients**        1,085 (97.2)                                    31 (2.8)                                                                     464 (88.4)   61 (11.6)            296 (31.5)   643 (68.5)   
  **Age (yr)**               70 (63-75)                                      71 (64-82)                                     0.378                         70 (59-76)   68 (58-78)   0.817   71 (63-77)   68 (58-75)   0.003
  **Age category (yr)**                                                                                                                                                                                               
   0-50                      19 (1.8)                                        2 (6.5)                                        0.027                         48 (10.3)    6 (9.8)      0.816   20 (6.8)     55 (8.6)     0.086
   50-60                     169 (15.6)                                      3 (9.7)                                                                      74 (15.9)    12 (19.7)            38 (12.8)    125 (19.4)   
   60-70                     342 (31.5)                                      10 (32.3)                                                                    110 (23.7)   13 (21.3)            82 (27.7)    168 (26.1)   
   70-80                     431 (39.7)                                      8 (25.8)                                                                     167 (36.0)   19 (31.1)            115 (38.9)   221 (34.4)   
   ≥ 80                      124 (11.4)                                      8 (25.8)                                                                     65 (14.0)    11 (18.0)            41 (13.9)    74 (11.5)    
  **Performance status**                                                                                                                                                                                              
   0-1                       727 (67.0)                                      18 (58.1)                                      0.106                         302 (65.1)   44 (72.1)    0.356   194 (65.5)   464 (71.2)   0.172
   2-4                       51 (4.7)                                        4 (12.9)                                                                     23 (5.0)     4 (6.6)              13 (4.4)     19 (3.0)     
   Unknown                   306 (28.3)                                      9 (29.0)                                                                     139 (30.0)   13 (21.3)            89 (30.1)    166 (25.8)   
  **Histology**                                                                                                                                                                                                       
   Adenocarcinoma            329 (30.3)                                      7 (22.6)                                       0.349                         204 (44.4)   29 (47.5)    0.109   166 (56.1)   514 (79.9)   \< 0.001
   Squamous cell carcinoma   387 (35.7)                                      11 (35.5)                                                                    134 (28.9)   16 (26.2)            64 (21.6)    27 (4.2)     
   Small cell lung cancer    216 (19.9)                                      10 (32.3)                                                                    54 (11.6)    12 (19.7)            28 (9.5)     30 (4.7)     
   Others                    153 (14.1)                                      3 (9.7)                                                                      72 (15.5)    4 (6.6)              38 (12.8)    72 (11.2)    
  **NSCLC stage**                                                                                                                                                                                                     
   I                         189 (21.7)                                      7 (33.3)                                       0.752                         103 (25.1)   12 (24.5)    0.698   75 (28.0)    245 (40.0)   0.006
   II                        98 (11.3)                                       2 (9.5)                                                                      23 (5.6)     4 (8.2)              22 (8.2)     38 (6.2)     
   III                       213 (24.5)                                      4 (19.0)                                                                     76 (18.5)    12 (24.5)            36 (13.4)    58 (9.5)     
   IV                        356 (41.0)                                      8 (38.1)                                                                     204 (49.8)   21 (42.9)            129 (48.1)   266 (43.4)   
   Unknown                   13 (1.5)                                        0                                                                            4 (1.0)      0                    6 (2.2)      6 (1.0)      
  **SCLC**                                                                                                                                                                                                            
   Limited                   87 (40.3)                                       4 (40.0)                                       0.908                         14 (25.9)    7 (58.3)     0.085   7 (25.0)     7 (23.3)     0.882
   Extensive                 125 (57.9)                                      6 (60.0)                                                                     38 (70.4)    5 (41.7)             21 (75.0)    23 (76.7)    
   Unknown                   4 (1.9)                                         0                                                                            2 (3.7)      0                    0            0            

Values are presented as number (%) or median (interquartile range). NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.

###### 

Risk factors for mortality in patients with NSCLC assessed by Cox proportional hazards model

                             Univariate analysis   Multivariate analysis                                    
  -------------------------- --------------------- ----------------------- ---------- ------- ------------- ----------
  **Age**                    1.036                 1.028-1.043             \< 0.001   1.020   1.012-1.028   \< 0.001
  **Male sex**               2.112                 1.788-2.494             \< 0.001   1.704   1.326-2.182   \< 0.001
  **Ever-smoker**            1.772                 1.572-2.056             \< 0.001   1.038   0.829-1.298   0.747
  **BMI**                    0.895                 0.876-0.915             \< 0.001   0.954   0.930-0.979   \< 0.001
  **Performance status**                                                                                    
   0-1 (ref)                 1.000                                                    1.000                 
   2-4                       3.166                 2.453-4.085             \< 0.001   1.410   1.012-1.964   0.042
  **Clinical stage**                                                                                        
   I (ref)                   1.000                                                    1.000                 
   II                        3.539                 2.406-5.203             \< 0.001   2.494   1.602-3.881   \< 0.001
   III                       7.946                 5.883-10.734            \< 0.001   4.141   2.854-6.007   \< 0.001
   IV                        13.634                10.330-17.994           \< 0.001   6.972   4.861-9.999   \< 0.001
  **Histology**                                                                                             
   Adenocarcinoma (ref)      1.000                                                    1.000                 
   Squamous cell carcinoma   1.833                 1.575-2.133             \< 0.001   1.187   0.994-1.430   0.053
  **Treatment**                                                                                             
   Surgery (ref)             1.000                                                    1.000                 
   Non-surgical treatment    6.516                 5.364-7.916             \< 0.001   2.214   1.711-2.864   \< 0.001
   Best supportive care      15.733                12.044-20.552           \< 0.001   4.954   3.495-7.021   \< 0.001

NSCLC, non-small cell lung cancer; CI, confidence interval; BMI, body mass index.

###### 

Risk factors for mortality in patients with small cell lung cancer assessed using Cox proportional hazards models

                                 Univariate analysis   Multivariate analysis                                    
  ------------------------------ --------------------- ----------------------- ---------- ------- ------------- ----------
  **Age**                        1.042                 1.028-1.057             \< 0.001   1.036   1.019-1.054   \< 0.001
  **Male sex**                   1.045                 0.754-1.448             0.793                            
  **Ever-smoker**                0.705                 0.518-0.959             0.026      0.867   0.588-1.280   0.473
  **BMI**                        0.910                 0.877-0.945             \< 0.001   0.938   0.901-0.977   0.002
  **Performance status**                                                                                        
   0-1 (ref)                     1.000                                                    1.000                 
   2-4                           3.106                 1.947-4.955             \< 0.001   2.436   1.379-4.305   0.002
  **Clinical stage**                                                                                            
   Limited (ref)                 1.000                                                    1.000                 
   Extensive                     2.262                 1.762-2.903             \< 0.001   2.331   1.719-3.160   \< 0.001
  **Treatment**                                                                                                 
   Anti-cancer treatment (ref)   1.000                                                    1.000                 
   Best supportive care          4.925                 3.514-6.904             \< 0.001   2.173   1.320-3.576   0.002

CI, confidence interval; BMI, body mass index.

###### 

Characteristics of patients with stage IV adenocarcinoma

                                           Total        Men          Women        p-value
  ---------------------------------------- ------------ ------------ ------------ ----------
  **No. of patients**                      571          339 (59.4)   232 (40.6)   
  **Age (yr)**                             68 (58-76)   67 (58-74)   70 (57-76)   0.168
  **Ever-smoker(n=561)**                   272 (48.5)   255 (76.3)   17 (7.5)     \< 0.001
  **BMI (kg/m^2^)**                        22.6±3.3     22.4±3.3     22.9±3.3     0.060
  **Performance status (n=414)**                                                  
   0-1                                     386 (93.2)   227 (92.3)   159 (94.6)   0.346
   2-4                                     28 (6.8)     19 (7.7)     9 (5.4)      
  ***EGFR* mutation status (n=496)**                                              
   Positive                                182 (36.8)   77 (26.6)    105 (51.2)   \< 0.001
   Negative                                313 (63.2)   213 (73.4)   100 (48.8)   
  ***EGFR* target agent usage**                                                   
   Yes                                     122 (67.0)   48 (62.3)    74 (70.5)    0.249
   No                                      60 (33.0)    29 (37.7)    31 (29.5)    
  ***ALK* translocation status (n=109)**                                          
   Positive                                15 (13.8)    7 (12.1)     8 (15.7)     0.584
   Negative                                94 (86.2)    51 (87.9)    43 (84.3)    
  ***ALK* target agent usage**                                                    
   Yes                                     7 (46.7)     1 (14.3)     6 (75.0)     0.041
   No                                      8 (53.3)     6 (85.7)     2 (25.0)     

Values are presented as median (interquartile range), number (%), or mean±standard deviation. BMI, body mass index; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.
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